Functional expression of B7/BB1 on activated T lymphocytes. by Azuma, M et al.
UCSF
UC San Francisco Previously Published Works
Title
Functional expression of B7/BB1 on activated T lymphocytes.
Permalink
https://escholarship.org/uc/item/6pw7t0cq
Journal
The Journal of experimental medicine, 177(3)
ISSN
0022-1007
Authors
Azuma, M
Yssel, H
Phillips, JH
et al.
Publication Date
1993-03-01
DOI
10.1084/jem.177.3.845
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Br ie f  De~nl t ive  Repor t  
Functional Expression of B7/BB1 on Activated 
T Lymphocytes 
By Miyuk i  Azuma,  1 Hans Yssel, 1 Joseph H.  Phillips, Hergen Spits, 
and Lewis L. Lanier 
From the DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, California 
94304 
Summary 
B7/BB1 is a membrane differentiation antigen expressed on activated B cells, macrophages, and 
dendritic ells that binds to a counter-receptor, CD28, expressed on T lymphocytes and thymocytes. 
Interaction between CD28 and B7 results in potent costimulation of T cell activation initiated 
via the CD3/T cell receptor complex. We now report that B7 is also expressed on activated 
human peripheral blood T cells, CD4 T cell clones, CD8 T cell clones, and natural killer cell 
clones. B7 appears relatively late after T cell activation, can be detected on both CD4 and CD8 
T cell subsets, and is present on antigen-specific, major histocompatibility complex-restricted 
CD4 and CD8 T cell clones. Expression of B7 on activated T cells was confirmed by 
immunoprecipitation from 12SI-labded activated T cells and by detection of B7 transcripts. A
B7 ~ CD4 + T cell clone was able to stimulate aprimary allogeneic mixed lymphocyte response 
using small, resting peripheral blood T cells as responders. The alloantigen-induced proliferative 
response and cytokine production was partially inhibited by anti-B7 monoclonal antibody. Since 
activated T cells can coexpress both CD28 and its counter-receptor, B7, this suggests that activated 
T cells may be capable of autocrine costimulation via the CD28 activation pathway. 
B 7/BB1 is a cell surface antigen expressed on activated Bcells, macrophages, and dendritic ells (1-3). While B7 
is constitutively expressed on dendritic cells (3), it is only 
present in substantial levels after activation of B cells and mono- 
cytes. This antigen is upregulated on B cells after infection 
with EBV (2) or after stimulation with anti-Ig (1) or anti- 
HLA-DR (4). Levels of B7 expression i duced by anti-Ig can 
be increased by Ib2 or II-4 (5). IFN-3, is capable of inducing 
B7 expression on monocytes (6). B7 is a 50-70-kD glycopro- 
tein and is encoded by a gene that is a member of the Ig 
superfamily (7). 
B7 binds to CD28 (8), a cell surface disulfide-linked 
homodimer that is constitutively expressed on thymocytes 
and the majority of T lymphocytes (9, 10). The interaction 
between CD28 and B7 results in augmentation of T cell ac- 
tivation initiated through the TCR (4, 8, 11-13). CD28 
costimulation of T cells results in induction of II.-2 transcrip- 
tion (14) and stabilization of cytokine mRNA (15), and is 
resistant to inhibition by r A (16). In a prior study, 
it was observed that HTLV-I-transformed T cells may also 
express B7 (17), suggesting the possibility that T cells may 
coexpress both CD28 and its counter-receptor under certain 
i The first two authors contributed qually to these studies. 
circumstances. Herein, we have investigated whether normal, 
nontransformed T cells are capable of expressing functional 
B7 antigens. 
Materials and Methods 
Preparation of Lymphocytes and Cell Culture. Human peripheral 
blood was obtained from the Stanford Blood Center (Palo Alto, 
CA). PBMC were isolated by Ficoll/Hypaque gradient centrifuga- 
tion. Small, resting T cells were isolated using Percoll density gra- 
dients after removal of B cells and monocytes by plastic and nylon 
wool adherence, aspreviously described (13). Cells were cultured 
in Yssel's modified Iscove's medium (18) or RPMI 1640 (JRH 
Biosdences, Lexena, KS) containing 10% FCS (JKI-I Biosdences), 
t-glutamine, and antibiotics. Human rlL-2 was generously provided 
by Dr. Gerard Zurawski (DNAX). A series of CD4 § T cell dones, 
CD8 + T cell clones, and NK cell clones was established from 
normal PBL. Clones were cultured in medium supplemented with 
rlI.-2 and were restimulated using PHA, irradiated PBMC, and ir- 
radiated EBV B lymphoblastoid ceils, as described previously (18). 
The properties of the antigen-spedfic T cell dones have been de- 
scribed previously (19-22). 
mAbs, Immunofluorescencg a d Flow Cytometry. Methods ofim- 
munofluorescent staining, flow cytometry, and data analysis have 
been described previously (23). Flow cytometry was performed using 
a FACScan | or FACStar Flus | (Becton Dickinson & Co., Moun- 
tain View, CA). All mAbs were generously provided by Becton 
Dickinson & Co., unless otherwise noted. BB1 mAb (2) was the 
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generous gift of Dr. Ed Clark (University of Washington, Seattle, 
WA). Anti-B7 mAbs L307 (IgG1) and L308 (IgM) were generated 
by immunizing C3H/HeJ mice with BT-transfected g cells and 
fusing immune splenocytes with Sp2/0 myeloma cells, as described 
previously (24). 
Biochemistry. Radioiodination, immunoprecipitation, a d elec- 
trophoresis were performed as previously described (25,.26). Ra- 
dioactive proteins were detected using a Phosphorlmager (Molec- 
ular Dynamics, Inc., Sunnyvale, CA). 
Results and Discussion 
Expression of B7 on Activated T Lymphocytes and T Cell 
Clones. Analysis of a series of human T cell clones indicated 
that the majority expressed B7 on the cell surface, as deter- 
mined by immunofluorescence and flow cytometry. Expres- 
sion of B7 on T cell clones was not restricted to a particular 
subset since both CD3+CD4 + T cell clones (14 of 16 ex- 
amined) and CD3+CD8 + T cell clones (14 of 14 exam- 
ined) were found. Moreover, B7 was also present on 
CD3-CD56 + NK cell clones (five of five examined), but 
was not detected on freshly isolated PBL NK cells (not 
shown). The levels of B7 varied between different clones and 
ranged from very high levels of expression to undetectable. 
Most of the B7 + T cell clones examined coexpressed the 
counter-receptor, CD28, whereas all B7 + NK cell clones 
were CD28 negative. Representative T and NK cell clones 
are shown in Fig. 1. Although the antigenic specificity of 
most of the T cell clones surveyed in our panel was not de- 
termined, B7 was detected on several well-characterized T 
cell clones of known specificity and function. For example, 
HY-827 is a CD4 +, HLA-DR3-restricted T cell clone that 
recognizes a peptide of tetanus toxoid (19), HY-06 is a 
CD4 +, HLA-DR3-restricted T cell clone that recognizes 
mycobacterial HSP-65 antigen (20), AG150 is a CD4 +, 
HLA-DR4-restricted T cell clone recognizing the DerpI house 
dust mite allergen (21), and CTL Q66.40 is a CD8 + , HLA- 
A2-restricted T cell clone reacting with an influenza peptide 
(22) (Fig. 1). The presence of B7 on T cell clones was rela- 
tively stable over time, although differences in levels of ex- 
pression were observed. 
The presence of B7 on most T cell clones prompted us 
to examine induction of this antigen on PBL T cells. Consis- 
tent with prior findings, B7 was not detected on freshly iso- 
lated PBL T cells (Fig. 2). PBMC were stimulated with im- 
mobilized anti-CD3, and 100 IU/ml rib2 was added to the 
culture after 5 d. Cells were examined on days 1, 3, 5, 10, 
and 12 for induction of B7. Using these conditions, B7 ap- 
peared gradually on the T cells over the course of culture, 
and maximal expression occurred after 10 d when >80% of 
T cells coexpressed B7 (Fig. 2). The majority of both CD4 
and CD8 T cells were B7 + . Consistent results were ob- 
tained using PBMC from three independent donors. The rel- 
atively late induction and the low levels of expression on some 
T cell clones likely accounts for prior reports that activated 
T cells failed to express B7 (2, 17). 
CD4-AG150 
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Figure 1. Expression of B7 on T and NK cell clones. Representative 
CD4 + and CD8 + T cell clones and a CD3-,CD56 + NK cell done were 
stained with PE-conjugated anti-B7 mAb L307, PE-conjugated anti-CD28 
mAb L293, or PE-conjugated IgG1 control mAb. Samples were analyzed 
by flow cytometry. The x-axis represents fluorescence (four-decade log scale) 
and the y axis represents he relative cell number. Histograms from cells 
stained with control mAb (nearest the y-axis) are superimposed over the 
histograms of cells stained with anti-B7 or anti-CD28, as indicated. 
Biochemical Analysis ofT Cell-associated B7Antigen. The 
presence orB7 on activated T cell populations and T cell clones 
was confirmed by immunofluorescent staining using three 
different mAbs against B7 (i.e., BB1, L307, L308) (not shown). 
Specificity of the immunofluorescent staining was substan- 
tiated by biochemical verification (Fig. 3). A CD4 + T clone 
(AW27-19) and a polyclonal population of anti-CD3 and rib 
2-activated PBL T cells were 12si labeled, detergent lysed, 
and B7 antigen was immunoprecipitated and analyzed by SDS- 
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Figure 2. Induction of B7 on PBL T lymphocytes. Plastic tissue cul- 
ture flasks (Falcon Labware, Lincoln Park, NJ) were coated with 10/~g]ml 
anti-CD3 (Leu-4) in PBS for I h and then washed extensively. PBMC 
(106 cdls/ml) were activated by culture in anti-CD3-coated tissue culture 
flasks. After 5 d, the media were supplemented with 100 IU/ml rIL-2, 
and culture was continued. Freshly isolated PBL T cells (.4) and day 10 
activated PBL T cells (B) were stained with PE-conjugated anti-B7- and 
FITC-conjugated anti-CD3 (Leu-4), anti-CD4 (Leu-3a), or anti-CDSce 
(Leu-2a), or with FITC- and PE-conjugated control Ig. Samples were ana- 
lyzed by flow cytometry. Data are displayed as contour plots of correlated 
FITC and PE fluorescence (four-decade log scales). Quadrant markers were 
positioned to include >98% of control Ig stained ceils in the lower left. 
PAGE. Similar to the molecular mass of B7 expressed on EBV- 
transformed B cell lines (1, 2), the B7 glycoprotein on acti- 
vated T cells was also *50-70 kD. Expression of B7 in NK 
and T cell clones was further supported by detection of B7 
transcripts using reverse transcription and PCR. amplification 
(not shown). 
B7 + T Cell Clones Stimulate a Primary Alloantigen MLR. 
Prior studies have established that B7 costimulation is required 
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Figure 3. Immunoprecipitation orB7. B7 § CD4 + T cell done AW27- 
19 (see Fig. 1) and a polyclonal population of PBL T cells activated with 
anti-CD3 and 100 IU/ml rlL-2 for 12 d were labeled with 12si, lysed in 
1% NP-40 lysis buffer, and immunoprecipitated with formalin-fixed Staph- 
ylococcus aureus coated with rabbit anti-mouse Ig and control mouse Ig 
(C) or anti-B7 mAb L307 (25, 26). Antigens were eluted in sample buffer 
containing 10% 2-ME and were analyzed using 9% (/eft) or 10% (right) 
SDS-PAGE gels. 
for the ef~cient generation ofa primary MLR directed against 
aUoantigen (13, 27). mAbs against B7 partially inhibit an 
alloantigen-induced MLR (3, 4), and transfection of B7- 
negative B lymphoma cell lines with B7 cDNA substantially 
augments heir ability to stimulate a primary T cell immune 
response (13, 27). The detection of B7 on activated T cells 
suggested that this may enable these T cells to act themselves 
as costimulators of a primary T cell response. Since human 
activated T cells express both MHC class II and class I in- 
tigens and B7, they might be expected to serve as stimulators 
of an allogeneic MLR. To examine this possibility, aCD4 + 
T cell clone expressing B7 (Fig. 1, CD4-AW27-19) was ir- 
radiated and used as the stimulator in a primary MLK cul- 
ture using freshly isolated small, resting PBL T cells as 
responders. As shown in Table 1, a vigorous MLR response 
was observed using small, resting PBL responder T cells from 
three different donors. Both the alloantigen-induced prolifer- 
ative response, as well as the secretion of IFN-% were par- 
tially ('~30-50%) inhibited by the presence of anti-B7 mAb, 
similar to the level of inhibition observed with anti-CD4 or 
anti-HLA-DR mAbs (Table 1). These results are comparable 
to prior reports that anti-B7 is capable of partially inhibiting 
alloantigen MLR generated with EBV B lymphoblastoid cells 
as stimulators (3, 4). 
Conclusions. B7 is not restricted in expression to "con- 
ventional" APC since this glycoprotein is also present on most 
activated T and NK cells. The ability of B7 + activated T
cell clones to stimulate a primary allogeneic MLR response 
substantiates the fact that expression of B7 is functionally 
competent. Prior studies have demonstrated that activated 
T and NK cell clones possess the ability to present peptide 
847 Azuma et al. Brief Definitive Report 
Table 1. B7 § T Cell Clone AFV27-I9 Stimulates Primary Allaantigen-induced Proliferative and Cytokine Responses 
Using Small, Resting T Cells as Responders 
[3H]TdR incorporation 
Small, resting Irradiated B7; T 
T responders stimulators mAb added Exp. 1 Exp. 2 Exp. 3 
cl)rrl x 10 -3 
+ + Control 20,3 (~-)* 15.3 ( - )  14.7 ( - )  
+ + c~B7 9.8 (51.7) 9.5 (37.9) 6.3 (57.3) 
+ + otCD4 8.5 (58.1) 7.5 (49.6) 7.7 (45.9) 
+ + ctHLA-DR 5.5 (72,4) 7.7 (50.9) 7.4 (49.8) 
+ + aCD4 + HLA-DR 2.5 (87.7) 7.3 (52.3) 2.6 (81.6) 
+ - None 1.0 2.3 1.0 
- + None 1.5 1.6 2.2 
IFN-3, production 
Exp. 1 Exp. 2 Exp. 3 
pg/ml 
+ + Control 5,650 ( - )*  6,685 ( - )  3,600 ( - )  
+ + c~B7 2,840 (48.2) 4,750 (28.9) 1,580 (56.1) 
+ + c~CD4 2,505 (55.6) 4.200 (37.1) 2,125 (40.9) 
+ + txHLA-DR 1,520 (73.1) 5,915 (11.5) 1,600 (55.5) 
+ + txCD4 + HLA-DR 975 (82.7) 500 (92.5) 870 (75.8) 
+ - None <50 <50 <50 
- + None <50 <50 <50 
Freshly isolated small, resting PBL T cells (2 x 10 s calls/well) from three different blood donors (Exps. 1-3) were cocultured with irradiated (4,000 
rad) B7 + T cell done AW27-19 (2 • 10 calls/well) in 96-well flat-bottomed plates (Falcon Labware) in a total volume of 200/~1, as indicated. 
Anti-BT, anti-HLA-DR, and anti-CD4 mAbs were added at 5/zg/ml. Cultures were incubated at37~ with 5% CO2 in a humidified atmosphere 
for 6 d. Cultures were hbeled for the final 4 h with 1 #Ci/well [3H]thymidine (New Enghnd Nuclear, Boston, MA), were harvested using a 96-well 
plate harvester (LKB, Pharmacia, Piscataway, NJ), and radioactivity was measured using a ~ scintilhtion counter. Small, resting PBL T cells isolated 
by PercoU gradient centrifugation are unable to respond to anti-CD3 stimuhition i the absence of appropriate accessory cells (13). The irradiated 
AW27-19 B7 + CD4 + T cells used as stimulators were >99% CD3 § and did not contain any detectable contaminating B cells or monocytes in
the population, as determined using flow cytometric analysis. For determination f IFN-q~ secretion, supernatants from MLR cultures were harvested 
after 48 h, and IFN-3, was measured by an ELISA using anti-IFNw-spedfic mAb (30). Data are expressed asIFN-3' (pg/ml) secreted per 106 cells 
(lower limit of detection was 50 pg/ml). 
* Numbers in parentheses represent percent inhibition, relative to control values. 
antigens in an antigen-specific, MHC-restricted fashion, al- 
though the antigen-processing capacity of T and NK cells 
are limited relative to macrophages (28, 29). Since activated 
T cells can coexpress both CD28 and its counter-receptor, 
B7, this suggests the possibility that activated T calls may 
be capable of autocrine costimulation via the CD28 activa- 
tion pathway under certain circumstances. 
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